Image credit- shutterstock
Australia’s new national incubator for vaccine and infectious disease innovation, Biointelect Venturer, has been launched, backed by $32.9 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) under the 2024 BioMedTech Incubator Grant Opportunity.
The initiative aims to transform early-stage scientific breakthroughs into viable health solutions with meaningful public health impact. Over four years (2026–2029), Biointelect Venturer will support three cohorts of innovators, providing Australian small and medium enterprises (SMEs) with the opportunity to advance vaccine and infectious disease innovations and attract further investment.
Successful applicants in the first cohort will begin in Q3 2026, with each project eligible to receive up to AUD 5 million, distributed in stages aligned with agreed milestones. Participants will also gain access to expert mentorship, infrastructure, and tailored strategic support designed to reduce development risk and accelerate commercial readiness.
Expressions of interest has opened on Monday, 17 November, and will be closing on 19 December. Interested applicants can register online for further information.
Biointelect Venturer marks a major step in building national capability to translate vaccine and infectious disease research into globally competitive health technologies.
